Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 28;29(3):295-304.
doi: 10.1097/QAD.0000000000000528.

Early viral suppression improves neurocognitive outcomes in HIV-infected children

Collaborators, Affiliations

Early viral suppression improves neurocognitive outcomes in HIV-infected children

Claudia S Crowell et al. AIDS. .

Abstract

Objective: To estimate the association of age of viral suppression and central nervous system penetration effectiveness (CPE) score with neurocognitive functioning among school-age children with perinatally acquired HIV infection (PHIV+).

Design: We analyzed data from two US-based multisite prospective cohort studies.

Methods: Multivariable general linear regression models were used to evaluate associations of age at viral suppression and CPE scores (of initial antiretroviral therapy regimen and weighted average) with the Wechsler Intelligence Scale for Children, Third or Fourth Edition neurocognitive assessments [Full-Scale Intelligence Quotient (FSIQ); Performance IQ/Perceptual Reasoning Index (PIQ/PRI); and Verbal IQ/Verbal Comprehension Index (VIQ/VCI)], adjusted for demographic and clinical covariates. Sensitivity analyses were stratified by birth cohort (before versus after 1996).

Results: A total of 396 PHIV+ children were included. Estimated differences in mean FSIQ (comparing virally suppressed versus unsuppressed children) by each age cutoff were 3.7, 2.2, 3.2, 4.4, and 3.9 points at ages 1, 2, 3, 4, and 5, respectively. For PIQ/PRI, estimated mean differences were 3.7, 2.4, 2.2, 4.6, and 4.5 at ages 1 through 5, respectively. In both cases, these differences were significant only at the age 4 and 5 thresholds. After stratifying by birth cohort, the association between age at suppression and cognitive function persisted only among those born after 1996. Age at viral suppression was not associated with VIQ/VCI; CPE score was not associated with FSIQ, verbal comprehension, or perceptual reasoning indices.

Conclusion: Virologic suppression during infancy or early childhood is associated with improved neurocognitive outcomes in school-aged PHIV+ children. In contrast, CPE scores showed no association with neurocognitive outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adjusted Mean Full Scale IQ Score by Viral Suppression at each Age Cutoff, Overall and by Birth Cohort. Children who achieved viral suppression at ≤4 and ≤5 years had significantly higher school-age FSIQ scores compared to children who did not achieve viral suppression by those age cutoffs. Multivariable models were adjusted for: birth cohort (in model for overall sample), age at time of WISC evaluation, WISC version, caregiver education level, Hispanic ethnicity, low birth weight, child's primary language.
Figure 2
Figure 2
Adjusted Mean PIQ/PRI Score by Viral Suppression at each Age Cutoff, Overall and by Birth Cohort. Performance IQ from WISC-III and Perceptual Reasoning Index from WISC-IV. Children who achieved viral suppression at ≤4 and ≤5 years had significantly higher school-age PIQ/PRI scores compared to children who did not achieve viral suppression by those age cutoffs. Multivariable models were adjusted for: birth cohort (in model for overall sample), age at time of WISC evaluation, WISC version, caregiver education level, low birth weight, child's primary language, race, sex, caregiver identity.

References

    1. Tamula MA, Wolters PL, Walsek C, Zeichner S, Civitello L. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. Pediatrics. 2003;112:679–684. - PubMed
    1. Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-age children. Eur J Paediatr Neurol. 2008;12:290–297. - PubMed
    1. Paramesparan Y, Garvey LJ, Ashby J, Foster CJ, Fidler S, Winston A. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J Acquir Immune Defic Syndr. 2010;55:134–136. - PubMed
    1. Crowell CS, Malee KM, Yogev R, Muller WJ. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy. Rev Med Virol. 2014 - PubMed
    1. Zink WE, Zheng J, Persidsky Y, Poluektova L, Gendelman HE. The neuropathogenesis of HIV-1 infection. FEMS Immunol Med Microbiol. 1999;26:233–241. - PubMed

Publication types

Substances